Citadel Advisors’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Citadel Advisors’s Portfolio PTX Stock Details PTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-590	Closed	-$17K	–	8920
2015 Q4	$17K	Sell	590 -1,910	-76%	-$57.8K	﹤0.01%	8061
2015 Q3	$79K	Buy	2,500 +490	+24%	+$23.4K	﹤0.01%	7191
2015 Q2	$119K	Buy	2,010 +1,690	+528%	+$119K	﹤0.01%	6914
2015 Q1	$34K	Buy	320 +70	+28%	+$6.67K	﹤0.01%	7631
2014 Q4	$23K	Sell	250 -730	-74%	-$69.6K	﹤0.01%	7719
2014 Q3	$75K	Sell	980 -1,020	-51%	-$80.3K	﹤0.01%	6636
2014 Q2	$180K	Buy	+2,000	New	+$123K	﹤0.01%	5679

Citadel Advisors's PTX Position: Q1 2019 in Review

Citadel Advisors sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q1 2019, closing a stake of 36,554 shares — an estimated $15K sold.

Citadel Advisors first reported a position in PTX in Q2 2014 and held it in 11 quarters. The position peaked at $1.92M in Q1 2015. 1 fund tracked by Wall St. Rank holds PTX as of Q1 2019.

Citadel Advisors reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q1 2019 after selling out during the quarter.
Citadel Advisors sold 36,554 Pernix Therapeutics Holdings, Inc. shares in Q1 2019, an estimated $15K.
Citadel Advisors first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2014 and held it in 11 quarters.
Citadel Advisors's Pernix Therapeutics Holdings, Inc. position peaked at $1.92M in Q1 2015.
1 fund tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q1 2019.

Based on Citadel Advisors's 13F filing for Q1 2019, filed 15 May 2019.